Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Bookmark and Share
Published: 16 Jun 2020
Views: 888
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

Prof Nikhil Munshi talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the KarMMa study.

The KarMMa study looks at CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel).

It resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Munshi provides a detailed account of the trial design, results, and toxicity profile.